biotech

Gilead Shares Fall After Hepatitis C treatment Sales Plunge

Gilead Shares Fall After Hepatitis C treatment Sales Plunge

Gilead Sciences Inc. (NASDAQ: GILD) reported its first quarter financial results after market close on Tuesday and missed analysts estimates. Shares fell by 7 percent after the opening bell on Wednesday.For the first quarter, Gilead reported revenue..

Bayer to Get Approval from Justice Department to Acquire Monsanto

Bayer to Get Approval from Justice Department to Acquire Monsanto

According to the person familiar with the matter, Bayer AG, the German drugs and pesticides group, is to get approval from the U.S. Justice Department to acquire Monsanto Company (NYSE: MON) for $62.5 billion.Shares of Monsanto rose 6.5% to $125.47 ..

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Inc. (NYSE: ABBV) reported its fourth quarter financial results for fiscal year 2017. The pharmaceutical company reported better than expected earnings sending shares 13.5 percent before market close on Friday.For the fourth quarter, AbbVie r..

Biogen Misses Earnings but Tops Revenue Estimates

Biogen Misses Earnings but Tops Revenue Estimates

Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter financial results for fiscal year 2017. The U.S. drug-maker fell short on earnings estimates, but topped revenue estimates, sending shares 3 percent higher during Thursday’s pre-marke..

Roche Pharma Acquires Ignyta for $1.7 billion

Roche Pharma Acquires Ignyta for $1.7 billion

Roche Holdings entered into a definitive agreement  with Ignyta Inc. (NASDAQ: RXDX) to acquire the biotech company specialized in the oncology field. Under the agreement, Roche agreed to purchase Ignyta at a price of $27.00 per share in cash. I..

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Inc (NASDAQ: RVNC) is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions. On Tuesday shares of the Revance jumped about 10% a after the company announced its n..

Novartis buys Advanced Accelerator Applications for $3.9 billion

Novartis buys Advanced Accelerator Applications for $3.9 billion

Novartis AG (NYSE: NVS) has entered into a written agreement with French pharmaceutical company, Advanced Accelerator Applications (NASDAQ: AAAP), for $3.9 billion. Novartis shares were up 0.8 percent and Advanced Accelerator Applications shares wer..